



Electronic Information Disclosure Statement

HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE

Application: 
09/930591

Confirmation: 3174

Applicant(s): Matti Sallberg

Docket
Number: TRIPEP028AUS

Group Art











Unit:

Examiner: Unassigned

search string: (4946778 or 4950647 or 5350671 or 5371017 or 5372928 or 5585258 or 5589466 or 5597691 or 5670152 or 5670153 or 5679342 or 5683864 or 5698390 or 5712087 or 5712088 or 5712145 or 5714596 or 5728520 or 5756312 or 5766845 or 5767097 or 5856437 or 5863719 or 5871903 or 5885799 or 5932556 or 5942234 or 5959092 or 5968775 or 5989905 or 6027729 or 6056961 or 6060068 or 6063380 or 6063772 or 6071693 or 6074816 or 6074846 or 6074852 or 6096541 or 6130326 or 6150087 or 6150337 or 6171782 or 6190864 or 6194140 or 6214583 or 6235888 or 6274148 or 6297370 or 20020004048).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
	P01	4946778	1990-08-07		Ladner et al.	—	—
	P02	4950647	1990-08-21		Robins et al.	—	—
	P03	5350671	1994-09-27		Houghton et al.	—	—
	P04	5371017	1994-12-06		Houghton et al.	—	—
	P05		1994-12-13		Miyamura et al.	—	—

Barquent

09/06/2002

BOL

Class/subclass

		5372928				
L	P06	5585258	1996-12-17		Houghton et al.	-
L	P07	5589466	1996-12-31		Felgner et al.	-
L	P08	5597691	1997-01-28		Houghton et al.	-
L	P09	5670152	1997-09-23		Weiner et al.	-
L	P10	5670153	1997-09-23		Weiner et al.	-
	P11	5679342	1997-10-21		Houghton et al.	-
	P12	5683864	1997-11-04		Houghton et al.	-
	P13	5698390	1997-12-16		Houghton et al.	-
	P14	5712087	1998-01-27		Houghton et al.	-
	P15	5712088	1998-01-27		Houghton et al.	-
	P16	5712145	1998-01-27		Houghton et al.	-
	P17	5714596	1998-02-03		Houghton et al.	-
	P18	5728520	1998-03-17		Weiner et al.	-
	P19	5756312	1998-03-26		Weiner et al.	-
	P20	5766845	1998-06-16		Weiner et al.	-
	P21	5767097	1998-06-16		Tam	-
	P22	5856437	1999-01-05		Miyamura et al.	-
	P23	5863719	1999-01-26		Houghton et al.	-
	P24	5871903	1999-02-16		Miyamura et al.	-
	P25	5885799	1999-03-23		Houghton et al.	-
	P26	5932556	1999-08-03		Tam	-
	P27	5942234	1999-08-24		Ralston et al.	-
	P28	5959092	1999-09-28		Miyamura et al.	-
	P29	5968775	1999-10-18		Houghton et al.	-
	P30	5989905	1999-11-23		Houghton et al.	-
	P31	6027729	2000-02-22		Houghton et al.	-
	P32	6056961	2000-05-02		Lavie et al.	-
M	P33	6060068	2000-05-09		Doyle et al.	-

class/subclasses

B6	P34	6063380	2000-05-16		Chedid et al.		
	P35	6063772	2000-05-16		Tam		
	P36	6071693	2000-06-06		Cha et al.		
	P37	6074816	2000-06-13		Houghton et al.		
	P38	6074846	2000-06-13		Ralston et al.		
	P39	6074852	2000-06-13		Ralston et al.		
	P40	6096541	2000-08-01		Houghton et al.		
	P41	6130326	2000-10-10		Ramasamy et al.		
	P42	6150087	2000-11-21		Chien		
	P43	6150337	2000-11-21		Tam		
	P44	6171782	2001-01-09		Houghton et al.		
	P45	6190864	2001-02-20		Cha et al.		
	P46	6194140	2001-02-27		Houghton et al.		
	P47	6214583	2001-04-10		Cha et al.		
	P48	6235888	2001-05-22		Pachuk et al.		
	P49	6274148	2001-08-14		Ralston et al.		
✓	P50	6297370	2001-10-02		Cha et al.		

Published Applications

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

B2

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
	U01	20020004048	2002-01-10		Ralston et al.		

Signature

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.028AUSAPPLICATION NO.
09/930,591INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Matti SällbergFILING DATE
August 15, 2001GROUP
1642RECEIVED
OCT 03 2002
TECH CENTER 1600/2800

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BQC	1	6,303,292	10/16/01	Weiner et al.	-	-	
BQL	2	6,312,889	11/06/01	Houghton et al.	-	-	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BQC	3	EP 0 388 232	09/19/90	European Patent Office				
	4	EP 0 414 475	02/27/91	European Patent Office				
	5	WO 91/15575	10/17/91	WIPO				
	6	WO 92/19743	11/12/92	WIPO				
	7	WO 93/00365	01/07/93	WIPO				
	8	WO 93/06126	04/01/93	WIPO				
	9	WO 94/16737	08/07/94	WIPO				
	10	EP 0 450 931	06/12/96	European Patent Office				
	11	WO 96/28162	09/19/96	WIPO				
	12	WO 97/12043	04/03/97	WIPO				
	13	EP 0 543 924	06/18/97	European Patent Office				
	14	WO 97/26883	07/31/97	WIPO				
	15	WO 98/16184	04/23/98	WIPO				
	16	WO 98/16186	04/23/98	WIPO				
	17	EP 0 842 947	05/20/98	European Patent Office				
	18	WO 98/30223	07/16/98	WIPO				
	19	EP 0 693 687	07/28/99	European Patent Office				
	20	EP 0 556 292	12/29/99	European Patent Office				
	21	WO 00/44388	08/03/00	WIPO				
	22	EP 1 034 785	09/13/00	European Patent Office				
	23	EP 0 318 216	08/29/01	European Patent Office				
	24	EP 0 398 748	01/09/02	European Patent Office				
	25	WO 02/13855	02/21/02	WIPO				

EXAMINER

Baqganz

DATE CONSIDERED

09/16/2004

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Matti SällbergFILING DATE
August 15, 2001GROUP
1642

JTECH CENTER 160012900

OCT 0 9 2002

RECEIVED

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BOL	26	WO 02/14362	02/21/02	WIPO	—	—		

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
BOL	27	AASLD Abstracts 940, "Hepatitis C Virus NS5A Sequence Confrugation does not Predict Response to Induction Interferon Plus Ribavirin," <i>Hepatology</i> , p. 394A (2000).
	28	Chen et al., "Human and Murine Antibody Recognition is Focused on the ATPase/Helicase, but not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein," <i>Hepatology</i> , 28(1):219-224 (1998).
	29	Chen et al., "Detection of Hepatitis C Virus RNA in the Cell Fraction of Saliva Before and After Oral Surgery," <i>J. Med. Virol.</i> , 43:223-226 (1995).
	30	Chiang et al., "Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2," <i>Vaccine Strategies Against Microbial Pathogens</i> , 42.11-42.16, p. A949 (date unknown).
	31	Cotonat et al., "Pilot Study of Combination Therapy with Ribavirin and Interferon Alfa for the Retreatment of Chronic Hepatitis B e Antibody-Positive Patients," <i>Hepatology</i> , 31(2):502-506 (2000).
	32	Cramp et al., "Hepatitis C Virus-Specific T-Cell Reactivity During Intereron and Ribavirin Treatment in Chronic Hepatitis C," <i>Gastron. Enterol.</i> , 118:346-355 (2000).
	33	Encke et al., "Genetic Immunization Generates Cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model", <i>Journal of Immunology</i> , 161:4917-4923 (1998).
	34	Diepolder et al., "Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection," <i>Lancet</i> , 346(8981):1006-1007.
	35	Gordon et al., "Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations," <i>Journal of Infectious Diseases</i> , 181(1):42-50.
	36	Hsu et al., "Prospects for a Hepatitis C Virus Vaccine", <i>Clin Liver Dis</i> , 3(4):901-915 (1999).
	37	Huffman et al., "In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses," <i>Antimicrob. Agents. Chemother.</i> , 3(2):235 (1973).
	38	Jin et al., "Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA Helicase," <i>Arch. Biochem. Biophys.</i> , 323:47-53 (1995).
	39	Kakumu et al., "Pilot Study of Ribavirin and Interferon- for Chronic Hepatitis B," <i>Hepatology</i> , 18(2):258-263 (1993).
	40	Kato, "Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation," <i>Microb. Com. Genomics</i> , 5(3):129-151 (2000).
	41	Kwong et al., "Hepatitis C virus NS3/4A protease," <i>Antiviral Res.</i> , 41(1):67-84 (1999).
	42	Kwong et al., "Structure and function of hepatitis C virus NS3 helicase," <i>Curr. Top. Microbiol. Immunol.</i> , 242:171-196 (2000).
	43	Lawrence et al., "Advances in the treatment of hepatitis C," <i>Adv. Intern. Med.</i> , 45:65-105 (2000).
	44	Li et al., "Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation," <i>Science</i> , 288:2219-2222 (2000).
	45	Marquardt et al., "Ribavirin inhibits mast cell mediator release," <i>J. Pharmacol. Exp. Therapeutics</i> , 240(1):145-149 (1987).
	46	Marshall et al., "Detection of HCV RNA by the asymmetric gap ligase chain reaction," <i>PCR Methods and Applications</i> , 4(2):80-84 (1994).
✓	47	Memar O. et al., "Antiviral Agents in Dermatology; Current Status and Future Prospects," <i>Internation Journal of Dermatology</i> , 34(9):597-606 (1995).

EXAMINER

Bargen L.

DATE CONSIDERED

09/16/2004

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT


(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Matti SällbergFILING DATE
August 15, 2001GROUP
1642

TECH CENTER 1600/2900

OCT 23 2002

RECEIVED



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
BQC	48 Missale et al., "Different clinical behaviours of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response," <i>J. Clin. Invest.</i> , 98(3):706-714 (1996).
	49 Neuberger et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , 312:604-608 (1984).
	50 Pape et al., "Role of the specific T-cell response for clearance and control of hepatitis C virus," <i>J. Viral. Hepat.</i> , Supp. 6, 1:36-40 (1999).
	51 Peavy et al., "Inhibition of murine plaque-forming cell responses in vivo by ribavirin," <i>J. Immunology</i> , 126(3):861-864 (1981).
	52 Powers et al., "Selective inhibition of functional lymphocyte subpopulations by ribavirin," <i>Antimicrob. Agents. Chemother.</i> , 22(1):108-114 (1982).
	53 Proust B. et al., "Two Successive Hepatitis C Virus Infections in an Intravenous Drug User," <i>Journal of Clinical Microbiology</i> , 38(8):3125-3127 (2000).
	54 Ramasamy et al., "Monocyclic L-Nucleosides with Type 1 Cytokine-Inducing Activity," <i>Journal of Medicinal Chemistry</i> , 43(5):1019-1028 (2000).
	55 Sällberg et al., "Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens," <i>Journal of Virology</i> , 71:5295-5303 (1997).
	56 Sällberg and Hultgren, "Vaccines Containing Ribavirin and Methods of use Thereof," U.S. Patent Application Serial No. 09/929,955, filed August 15, 2001.
	57 Sällberg and Hultgren, "Vaccines Containing Ribavirin and Methods of use Thereof," U.S. Patent Application Serial No. 10/104,966, filed March 22, 2002.
	58 Schulof R. S., "Clinical, Virologic, and Immunologic Effects of Combination Therapy with Ribavirin and Isoprinosine in HIV-Infected Homosexual Men," <i>Journal of Acquired Immune Deficiency Syndromes</i> , 3(5):485-492 (1990).
	59 Sidwell et al., "Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide," <i>Science</i> , 177(50):705-706 (1972).
	60 Smith et al., "Molecular Engineering of the <i>Autographa californica</i> Nuclear Polyhedrosis Virus Genome: Deletion Mutations Within the Polyhedrin Gene," <i>Journal of Virology</i> , 46:584 (1983).
	61 Spector et al., "The Antiviral Effect of Zidovudine and Ribavirin in Clinical Trials and the Use of p24 Antigen Levels as a Virologic Marker," <i>Journal of Infectious Diseases</i> , 159(5):822-828 (1989).
	62 Szybalska and Szybalska, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait," <i>Proc Natl Acad Sci USA</i> , 48:2026 (1962).
	63 Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <i>Nature</i> , 314:452-454 (1985).
	64 Tam et al., "Ribavirin Polarizes Human T Cell Responses Towards a Type 1 Cytokine Profile," <i>Journal of Hepatology</i> , 30(3):376-382 (1999).
	65 Tan et al., "How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A," <i>Virology</i> , 284(1):1-12 (2001).
	66 Vaitukaitis et al., "A method for producing specific antisera with small doses of immunogen," <i>J. Clin. Endocrinology Metab.</i> , 33(6):988-991 (1971).
	67 Walsh et al., "Update on chronic viral hepatitis," <i>Postgrad Medical Journal</i> , 77(910):498-505 (2001).
	68 Wang et al., "Synthesis and Cytokine Modulation Properties of Pyrrolo[2,3,-d]-4-pyrimidone Nucleosides," <i>J. Med. Chem.</i> , 43(13):2566-2574 (2000).
✓	69 Zhang et al., "Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside triphosphatase/helicase domain of the hepatitis C virus nonstructural 3 protein," <i>Clin. Diagn. Lab. Immunol.</i> , 7(1):58-63 (2000).

EXAMINER

Bazant

DATE CONSIDERED

09/16/2004

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED
TECH CENTER 1600/2900
OCT 09 2002
SHEET 4 OF 4

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.028AUS	APPLICATION NO. 09/930,591
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Matti Sällberg	
		FILING DATE August 15, 2001	GROUP 1642



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
BLO	70	Zhang et al., "Molecular basis for antibody cross-reactivity between the hepatitis C virus core protein and the host-derived GOR protein," <i>Clin. Exp. Immunol.</i> , 96(3):403-409 (1994).
BLO	71	http://www.msi.com/life/products/cerius2/modules/analogbuilder.html , C2Analog Builder, July 6, 2000.

S:\DOCS\DA\DAI-1722.DOC
091202

EXAMINER	<i>Buggenl:</i>	DATE CONSIDERED	<i>09/16/2002</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.028AUSAPPLICATION NO.
09/830,591INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Matti SallbergFILING DATE
August 15, 2001GROUP
Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BLI	2002/0165172 A1	11/07/02	Sallberg et al.	514	44	
↓	2002/0183508 A1	12/05/02	Maertens et al.	536	23.72	
↓	2002/0187945 A1	12/12/02	Tam	514	43	

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	

S:\DOCS\ESFESF-6193.DOC
020703

EXAMINER	<i>Baoguan</i>	DATE CONSIDERED	<i>09/16/2004</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIEP.028AUS	APPLICATION NO. 09/930,591
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Sallberg, Matti	
		FILING DATE August 15, 2001	GROUP 1648




U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BCC	1.	6,653,125	11/25/03	Donnelly et al.			

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BCCr	2.	WO 98/37180	08/27/98	WIPO				
J	3.	WO 99/04008	01/28/99	WIPO				
	4.	WO 99/28482	06/10/99	WIPO				
	5.	WO 01/38360	05/31/01	WIPO				
	6.	WO 01/96875	12/20/01	WIPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
BCC	7.	Hahn et al., "NS3-4A of Hepatitis C Virus is a Chymotrypsin-Like Protease," Journal of Virology, The American Society for Microbiology, 69(4):2534-2539 (1995).

S:\DOCS\ESF\ESF-7385.DOC

EXAMINER <i>Buoguen</i>	DATE CONSIDERED <i>03/16/2004</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



SHEET 1 OF 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.028AUSAPPLICATION NO.
09/930,951SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Matti SallbergFILING DATE
August 15, 2001GROUP
Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BLC	1	6,514,731	02/04/03	Valenzuela et al.	—	—	
	2	2003/0007977	01/09/03	Wheeler et al.	—	—	
	3	2003/0008274	01/09/03	Maertens et al.	—	—	
	4	2003/0032005	02/13/03	Maertens et al.	—	—	
	5						
	6						
	7						
	8						
	9						
	10						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	11							
	12							
	13							
	14							
	15							
	16							

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	17	
	18	
	19	
	20	
	21	

S:\DOCS\ESF\ESF-6309.DOC
030303


EXAMINER

Baogun Li

DATE CONSIDERED

08/16/2004

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.028AUS	APPLICATION NO. 09/830,591
	APPLICANT Matti Sallberg		
	FILING DATE August 15, 2001	GROUP 1648	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BDC	1	0 318 216	05/31/89	EP	—	—		
	2	WO 97/47358	12/18/97	PCT	—	—		
	3	WO 98/34640	08/13/98	PCT	—	—		
	4	WO 03/031588 A2	04/17/03	PCT	—	—		
	5	WO 03/031588 A3	04/17/03	PCT	—	—		

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
BDC	6	Andre et al., "Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage," <i>Journal of Virology</i> , 72(2):1497-1503 (1998).	
	7	DATABASE GENBANK [Online] 12/02/94, retrieved from NCBI Database accession no. I06434, XP002278035.	
	8	DATABASE REGISTRY [Online] No. 511600-20-7, XP02278058 abstract & WO 03/031588A, 04/17/03, Seq ID No. 1, 10 and 11 claims	
	9	Lazdina et al., "Humoral and CD4 ⁺ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th 1-like responses more effectively as a DNA-based immunogen than as a recombinant protein," <i>Journal of General Virology</i> , 82:1299-1308 (2001).	

S:\DOCS\IES\FRESF-7936.DOC
062404

EXAMINER	Baegen L	DATE CONSIDERED	09/16/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.028AUS	APPLICATION NO. 09/030,591
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Sällberg, Matti	
		FILING DATE August 15, 2001	GROUP 1648



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BL	1	6,541,011	04/0103	Punnonen et al.	—	—	
	2						
	3						
	4						
	5						
	6						
	7						
	8						
	9						
	10						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BL	11	WO 96/09805	04/04/96	PCT	—	—		
	12	WO 96/33739	10/31/96	PCT	—	—		
	13							
	14							
	15							
	16							

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
BL	17	BLASTN 2.2.9., May 01, 2004.
	18	Kumar et al., "Sequence, expression and reconstitution of an HCV genome from a British isolate derived from a single blood donation," Journal of Viral Hepatitis, 7:459-465, (2000).
	19	NCBI, Genbank, M32084. Hepatitis C Virus . . . [gi:329875] August 02, 1993.
	20	
	21	

S:\DOCS\ESPESF-8006.DOC

EXAMINER <i>Saegunt</i>	DATE CONSIDERED <i>09/16/2004</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	